Related references
Note: Only part of the references are listed.Optimizing synthetic nucleic acid and protein nanocarriers: The chemical evolution approach
Franziska Freitag et al.
ADVANCED DRUG DELIVERY REVIEWS (2021)
Polyphosphazenes for the delivery of biopharmaceuticals
Wei-Hsin Hsu et al.
JOURNAL OF APPLIED POLYMER SCIENCE (2020)
The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy
Annemieke Aartsma-Rus et al.
NUCLEIC ACID THERAPEUTICS (2020)
Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy
Philippine Aupy et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria
Tracy L. McGregor et al.
ELIFE (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A pharmacokinetic-pharmacodynamic model based on multi-organ-on-a-chip for drug-drug interaction studies
Kenta Shinha et al.
BIOMICROFLUIDICS (2020)
Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug
Alexandre J. Debacker et al.
MOLECULAR THERAPY (2020)
Advances in oligonucleotide drug delivery
Thomas C. Roberts et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy
Annabelle Biscans et al.
NUCLEIC ACIDS RESEARCH (2020)
Mist begins to clear for lung delivery of RNA
Catherine Shaffer
NATURE BIOTECHNOLOGY (2020)
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Ai-Ming Yu et al.
PHARMACOLOGICAL REVIEWS (2020)
Inhaled RNA Therapy: From Promise to Reality
Michael Y. T. Chow et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Shape Matters: Gold Nanoparticle Shape Impacts the Biological Activity of siRNA Delivery
Erin Morgan et al.
BIOCONJUGATE CHEMISTRY (2019)
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Eliane Sardh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Reassessment of Exosome Composition
Dennis K. Jeppesen et al.
CELL (2019)
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index
Wen Shen et al.
NATURE BIOTECHNOLOGY (2019)
Advances in therapeutic applications of extracellular vesicles
Oscar P. B. Wiklander et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis
Veena Mathew et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model
Lucia Echevarria et al.
NUCLEIC ACID THERAPEUTICS (2019)
Dendrimer-Enabled Therapeutic Antisense Delivery Systems as Innovation in Medicine
Serge Mignani et al.
BIOCONJUGATE CHEMISTRY (2019)
Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2019)
Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells
Shiyu Wang et al.
NUCLEIC ACID THERAPEUTICS (2019)
On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships
Christopher W. McAleer et al.
SCIENTIFIC REPORTS (2019)
Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient- derived cells and mice
Arnaud F. Klein et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Multiscale reverse engineering of the human ocular surface
Jeongyun Seo et al.
NATURE MEDICINE (2019)
The Pharmacokinetics of 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy
Sieto Bosgra et al.
NUCLEIC ACID THERAPEUTICS (2019)
Merging organoid and organ-on-a-chip technology to generate complex multi-layer tissue models in a human retina-on-a-chip platform
Kevin Achberger et al.
ELIFE (2019)
Glucagon-like peptide 1 (GLP-1)
T. D. Mueller et al.
MOLECULAR METABOLISM (2019)
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
J. Kim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Stimuli-Responsive Phosphorus-Based Polymers
Ian Teasdale
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY (2019)
Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
Markus Fusser et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect
Artur V. Cideciyan et al.
NATURE MEDICINE (2019)
Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias
Ronald A. M. Buijsen et al.
NEUROTHERAPEUTICS (2019)
Vesiclepedia 2019:a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles
Mohashin Pathan et al.
NUCLEIC ACIDS RESEARCH (2019)
Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways
Maire F. Osborn et al.
NUCLEIC ACIDS RESEARCH (2019)
Spinal Muscular Atrophy Therapies: ICER Grounds the Price to Value Conversation in Facts
Catherine I. Starner et al.
Journal of Managed Care & Specialty Pharmacy (2019)
Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads
Jayesh A. Kulkarni et al.
NANOSCALE (2019)
Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?
Janos Szebeni
DRUG DISCOVERY TODAY (2018)
Morpholino oligomers tested in vitro, in biofilm and in vivo against multidrug-resistant Klebsiella pneumoniae
Bruce L. Geller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Why dystrophin quantification is key in the eteplirsen saga
Annemieke Aartsma-Rus et al.
NATURE REVIEWS NEUROLOGY (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotides
Rudolph L. Juliano et al.
NUCLEIC ACIDS RESEARCH (2018)
Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2′-MOE-Modified Antisense Oligonucleotide
Padmakumar Narayanan et al.
TOXICOLOGICAL SCIENCES (2018)
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
Maja M. Janas et al.
NATURE COMMUNICATIONS (2018)
The Effects of 2-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2018)
A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides
Andreas Dieckmann et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Extracellular Vesicle Heterogeneity: Subpopulations, Isolation Techniques, and Diverse Functions in Cancer Progression
Eduard Willms et al.
FRONTIERS IN IMMUNOLOGY (2018)
PLGA-Based Nanoparticles in Cancer Treatment
Sima Rezvantalab et al.
FRONTIERS IN PHARMACOLOGY (2018)
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
C. Ammala et al.
SCIENCE ADVANCES (2018)
Aptamer-iRNAs as Therapeutics for Cancer Treatment
Mario M. Soldevilla et al.
PHARMACEUTICALS (2018)
Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer
Tianzhi Yang et al.
AAPS JOURNAL (2017)
A pumpless multi-organ-on-a-chip (MOC) combined with a pharmacokinetic-pharmacodynamic (PK-PD) model
Hyuna Lee et al.
BIOTECHNOLOGY AND BIOENGINEERING (2017)
Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach
Kaushik Thanki et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2017)
Mesoporous Silica Nanoparticles as Carriers for Intracellular Delivery of Nucleic Acids and Subsequent Therapeutic Applications
Wenzhang Cha et al.
MOLECULES (2017)
Cellular uptake and trafficking of antisense oligonucleotides
Stanley T. Crooke et al.
NATURE BIOTECHNOLOGY (2017)
Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases
Kathleen M. Schoch et al.
NEURON (2017)
Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs
Anastasia Khvorova
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Managing the sequence-specificity of antisense oligonucleotides in drug discovery
Peter H. Hagedorn et al.
NUCLEIC ACIDS RESEARCH (2017)
Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2017)
Exosomes: Therapy delivery tools and biomarkers of diseases
Lucio Barile et al.
PHARMACOLOGY & THERAPEUTICS (2017)
FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides
Annemieke Aartsma-Rus
NUCLEIC ACID THERAPEUTICS (2017)
Assessment of the Effects of 2'-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates
Scott P. Henry et al.
NUCLEIC ACID THERAPEUTICS (2017)
Inhibition of EGF Uptake by Nephrotoxic Antisense Drugs In Vitro and Implications for Preclinical Safety Profiling
Annie Moisan et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia
Sabine Sewing et al.
PLOS ONE (2017)
Safety of antisense oligonucleotide and siRNA-based therapeutics
Xuan Chi et al.
DRUG DISCOVERY TODAY (2017)
Delivery is key: lessons learnt from developing splice-switching antisense therapies
Caroline Godfrey et al.
EMBO MOLECULAR MEDICINE (2017)
Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts
Sebastien A. Burel et al.
NUCLEIC ACIDS RESEARCH (2016)
Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice
Jing-yun Li et al.
ACTA PHARMACOLOGICA SINICA (2016)
Peptides for nucleic acid delivery
Taavi Lehto et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Electroneutral composite polymersomes self-assembled by amphiphilic polyphosphazenes for effective miR-200c in vivo delivery to inhibit drug resistant lung cancer
Yan Peng et al.
BIOMATERIALS (2016)
Identification and Correction of Mechanisms Underlying Inherited Blindness in Human iPSC-Derived Optic Cups
David A. Parfitt et al.
CELL STEM CELL (2016)
Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience
Manon Hache et al.
JOURNAL OF CHILD NEUROLOGY (2016)
A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells
Carla L. Esposito et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles
Tsukasa Sugo et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA
Sam Chen et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Design of Ionizable Lipids To Overcome the Limiting Step of Endosomal Escape: Application in the Intracellular Delivery of mRNA, DNA, and siRNA
Damien Habrant et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames
Xue-hai Liang et al.
NATURE BIOTECHNOLOGY (2016)
Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity
Xue-Hai Liang et al.
NUCLEIC ACIDS RESEARCH (2016)
Establishment of a Predictive In Vitro Assay for Assessment of the Hepatotoxic Potential of Oligonucleotide Drugs
Sabine Sewing et al.
PLOS ONE (2016)
Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy
Suzan M. Hammond et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Considerations for the Characterization and Interpretation of Results Related to Alternative Complement Activation in Monkeys Associated with Oligonucleotide-Based Therapeutics
Scott P. Henry et al.
NUCLEIC ACID THERAPEUTICS (2016)
Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2′-O-Methoxyethyl Modified Antisense Oligonucleotide
Lijiang Shen et al.
NUCLEIC ACID THERAPEUTICS (2016)
Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
Nathalie M. Goemans et al.
PLOS ONE (2016)
Microfluidic organ-on-chip technology for blood-brain barrier research
Marinke W. van der Helm et al.
TISSUE BARRIERS (2016)
Aptamer-Mediated Targeted Delivery of Therapeutics: An Update
Silvia Catuogno et al.
PHARMACEUTICALS (2016)
siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes
Shigeo Matsuda et al.
ACS CHEMICAL BIOLOGY (2015)
Delivery of therapeutic oligonucleotides with cell penetrating peptides
Prisca Boisguerin et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
Richard S. Geary et al.
CLINICAL PHARMACOKINETICS (2015)
Species-Dependent Splice Recognition of a Cryptic Exon Resulting from a Recurrent Intronic CEP290 Mutation that Causes Congenital Blindness
Alejandro Garanto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Selective delivery of therapeutic single strand antimiRs by aptamer-based conjugates
Silvia Catuogno et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators
Ulrike Flierl et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
Ole B. Suhr et al.
ORPHANET JOURNAL OF RARE DISEASES (2015)
Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides
Jeffery A. Engelhardt et al.
TOXICOLOGIC PATHOLOGY (2015)
Functional Characterization of the spf/ash Splicing Variation in OTC Deficiency of Mice and Man
Ana Rivera-Barahona et al.
PLOS ONE (2015)
Antisense Oligonucleotide Therapies: The Promise and the Challenges from a Toxicologic Pathologist's Perspective
Kendall S. Frazier
TOXICOLOGIC PATHOLOGY (2015)
The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse
Aiping Zhang et al.
TOXICOLOGY REPORTS (2015)
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
Thomas Voit et al.
LANCET NEUROLOGY (2014)
Adsorption and Release of siRNA from Porous Silica
Jeremy L. Steinbacher et al.
LANGMUIR (2014)
Gold Nanoparticles for Nucleic Acid Delivery
Ya Ding et al.
MOLECULAR THERAPY (2014)
Sequence motifs associated with hepatotoxicity of locked nucleic acid-modified antisense oligonucleotides
Andrew D. Burdick et al.
NUCLEIC ACIDS RESEARCH (2014)
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
Yizhou Dong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
A Chemical View of Oligonucleotides for Exon Skipping and Related Drug Applications
Peter Jaerver et al.
NUCLEIC ACID THERAPEUTICS (2014)
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Fritz Eckstein
NUCLEIC ACID THERAPEUTICS (2014)
Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4
Miriam E. Jaax et al.
BLOOD (2013)
Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
Mark J. Graham et al.
CIRCULATION RESEARCH (2013)
Inorganic nanomaterials as delivery systems for proteins, peptides, DNA, and siRNA
Martin Malmsten
CURRENT OPINION IN COLLOID & INTERFACE SCIENCE (2013)
Endocytosis, Intracellular Traffic and Fate of Cell Penetrating Peptide Based Conjugates and Nanoparticles
Kez Cleal et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Gene-Silencing Antisense Oligomers Inhibit Acinetobacter Growth In Vitro and In Vivo
Bruce L. Geller et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
Gregory S. Thomas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape
Jerome Gilleron et al.
NATURE BIOTECHNOLOGY (2013)
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran et al.
NATURE PROTOCOLS (2013)
Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner
Erik Westein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Hepatotoxic Potential of Therapeutic Oligonucleotides Can Be Predicted from Their Sequence and Modification Pattern
Peter H. Hagedorn et al.
NUCLEIC ACID THERAPEUTICS (2013)
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo
Muthusamy Jayaraman et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Organs-on-chips: breaking the in vitro impasse
Andries D. van der Meer et al.
INTEGRATIVE BIOLOGY (2012)
Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow
Hyun Jung Kim et al.
LAB ON A CHIP (2012)
Assessing unintended hybridization-induced biological effects of oligonucleotides
Morten Lindow et al.
NATURE BIOTECHNOLOGY (2012)
Alginate: Properties and biomedical applications
Kuen Yong Lee et al.
PROGRESS IN POLYMER SCIENCE (2012)
Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis
Yan-dan Yao et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290
Rob W. J. Collin et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum
Liutao Du et al.
HUMAN MOLECULAR GENETICS (2011)
Biodistribution of Small Interfering RNA at the Organ and Cellular Levels after Lipid Nanoparticle-mediated Delivery
Bin Shi et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2011)
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
Sebahattin Cirak et al.
LANCET (2011)
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Lydia Alvarez-Erviti et al.
NATURE BIOTECHNOLOGY (2011)
Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
Hans Heemskerk et al.
MOLECULAR THERAPY (2010)
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
Akin Akinc et al.
MOLECULAR THERAPY (2010)
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents
C. A. Stein et al.
NUCLEIC ACIDS RESEARCH (2010)
Reconstituting Organ-Level Lung Functions on a Chip
Dongeun Huh et al.
SCIENCE (2010)
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
Rosie Z. Yu et al.
BIOCHEMICAL PHARMACOLOGY (2009)
The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2 '-O-methyl-RNA directed against telomerase in lung cancer cells
S. Taetz et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2009)
Antisense oligonucleotide pharmacokinetics and metabolism
Richard S. Geary
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Most mammalian mRNAs are conserved targets of microRNAs
Robin C. Friedman et al.
GENOME RESEARCH (2009)
In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping
Hans A. Heemskerk et al.
JOURNAL OF GENE MEDICINE (2009)
Rational Design of Antisense Oligomers to Induce Dystrophin Exon Skipping
Chalermchai Mitrpant et al.
MOLECULAR THERAPY (2009)
Accessing the therapeutic potential of immunostimulatory nucleic acids
Winfried Barchet et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Chemically modified siRNA: tools and applications
Jonathan K. Watts et al.
DRUG DISCOVERY TODAY (2008)
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akin Akinc et al.
NATURE BIOTECHNOLOGY (2008)
Cell-penetrating peptides for drug delivery across membrane barriers
Camilla Foged et al.
EXPERT OPINION ON DRUG DELIVERY (2008)
Induction of pluripotent stem cells from adult human fibroblasts by defined factors
Kazutoshi Takahashi et al.
CELL (2007)
Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models
Renaud Burrer et al.
JOURNAL OF VIROLOGY (2007)
Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension
Maurice A. Curtis et al.
SCIENCE (2007)
Blood-brain barrier delivery
William M. Pardridge
DRUG DISCOVERY TODAY (2007)
Mutations in the CEP290 (NPHP6) gene are a frequent cause of leber congenital amaurosis
Anneke I. den Hollander et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors
Kazutoshi Takahashi et al.
CELL (2006)
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras
James O. McNamara et al.
NATURE BIOTECHNOLOGY (2006)
Off-target effects by siRNA can induce toxic phenotype
Yuriy Fedorov et al.
RNA (2006)
Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo
AD Judge et al.
MOLECULAR THERAPY (2006)
Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron
NK Singh et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
EWM Ng et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Therapeutic potential of Toll-like receptor 9 activation
Arthur M. Krieg
NATURE REVIEWS DRUG DISCOVERY (2006)
Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response independent of toll-like receptor 9 or myeloid differentiation factor 88
JJ Senn et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
EW Song et al.
NATURE BIOTECHNOLOGY (2005)
Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs
HJ Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Pegaptanib for neovascular age-related macular degeneration
ES Gragoudas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Antisense and siRNA as agonists of Toll-like receptors
S Agrawal et al.
NATURE BIOTECHNOLOGY (2004)
Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation
J Vollmer et al.
IMMUNOLOGY (2004)
Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide
SP Henry et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2002)
Fomivirsen - Clinical pharmacology and potential drug interactions
RS Geary et al.
CLINICAL PHARMACOKINETICS (2002)
Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures
SC Semple et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2001)
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
C Wahlestedt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy
JW Miller et al.
EMBO JOURNAL (2000)